A large number of elderly @entity1 with @entity3052 ( @entity3052 ) are not offered treatments with curative intent, such as allogeneic @entity8 ( @entity8 ), because of fears of @entity137 and perceived futility of intensive treatment. Therefore, the outcomes of @entity8 in elderly @entity3052 @entity1 remain poorly defined. We performed a meta-analysis of all previous articles up until September 22, 2015 of @entity8 in @entity3052 @entity1 >60 years. The primary endpoints were @entity4557 ( @entity4557 ) and @entity1349 ( @entity1349 ) at 6 months and at 1, 2, and 3 years. A total of 13 studies (749 @entity1 ) were included. The pooled estimates and 95% confidence intervals (CI) for @entity4557 at 6 months, 1 year, 2 years, and 3 years were 62% (95% CI, 54% to 69%), 47% (95% CI, 42% to 53%), 44% (95% CI, 33% to 55%), and 35% (95% CI, 26% to 45%), respectively. The corresponding numbers for @entity1349 were 73% (95% CI, 66% to 79%), 58% (95% CI, 50% to 65%), 45% (95% CI, 35% to 54%), and 38% (95% CI, 29% to 48%), respectively. We found no evidence of publication bias in our primary endpoints, with the exception of relapse, where there appeared to be a relative lack of small studies with high relapse rates. Sensitivity analysis did not identify an overtly influential study for our primary endpoints, with 1 exception in 2-year @entity4557 analysis. The present analysis argues against significant publication bias and demonstrates consistency among reports despite differences in @entity1 -, disease-, center-, and transplantation-related characteristics. Our results suggest that reduced-intensity @entity8 is a viable treatment option for elderly @entity3052 @entity1 with a 3-year @entity4557 of 35% for those over the age of 60. These results argue against using age per se as the sole criterion against @entity8 and would help remove some of the barriers that often preclude curative intent treatment. Correct identification of @entity1 who would benefit from @entity8 can improve outcomes in this frequently undertreated population.

Outcomes of Allogeneic Stem Cell Transplantation in Elderly @entity1 with XXXX : A Systematic Review and Meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity8 :: ('MESH:D007674', 'Disease') :: ['SCT', 'stem cell transplantation'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity4557 :: ('MESH:D012008', 'Disease') :: ['RFS', 'relapse-free survival'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity3052 :: (MESH:D015470,Disease) :: ['Acute Myeloid Leukemia']
